# First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

> **NCT06795022** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 304 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** AZD9793 Intravenous (IV) monotherapy
- **DRUG:** AZD9793 Subcutaneous (SC) monotherapy

## Key facts

- **NCT ID:** NCT06795022
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-27
- **Primary completion:** 2028-02-25
- **Final completion:** 2028-07-25
- **Target enrollment:** 304 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06795022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06795022, "First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06795022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*